Elite in Cushing's disease

Giorgio Arnaldi

Palermo, IT 
Elite in Cushing's disease
Palermo, IT 
OverviewLocationsClinical Research

Overview

Giorgio Arnaldi practices in Palermo, Italy. Mr. Arnaldi is rated as an Elite expert by MediFind in the treatment of Cushing's disease. His top areas of expertise are Cushing's syndrome, Cushing's disease, Addison's Disease, Hormone Replacement Therapy (HRT), and Salpingo-Oophorectomy.

His clinical research consists of co-authoring 94 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 16 articles and participated in 2 clinical trials in the study of Cushing's disease.

Gender
Male

Locations

Palermo, 90127, Italy
Other Locations
Ancona, Italy
Marche, Italy
Via Tronto 10B, AN, Torrette, 60020, Italy
Italy
Messina, 98100, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

An Open-label Extension Study of Levoketoconazole (2S,4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome
An Open-label Extension Study of Levoketoconazole (2S,4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome
Enrollment Status: Completed
Publish Date: June 19, 2025
Intervention Type: Drug
Study Drug: Levoketoconazole
Study Phase: Phase 3
A Double-blind, Placebo-Controlled, Randomized Withdrawal Following Open Label Therapy Study to Assess the Safety and Efficacy of Levoketoconazole (2S, 4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome
A Double-blind, Placebo-Controlled, Randomized Withdrawal Following Open Label Therapy Study to Assess the Safety and Efficacy of Levoketoconazole (2S, 4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome
Enrollment Status: Completed
Publish Date: November 08, 2022
Intervention Type: Drug
Study Phase: Phase 3
An Open Label Study to Assess the Safety and Efficacy of COR-003 (Levoketoconazole) in the Treatment of Endogenous Cushing's Syndrome
An Open Label Study to Assess the Safety and Efficacy of COR-003 (Levoketoconazole) in the Treatment of Endogenous Cushing's Syndrome
Enrollment Status: Completed
Publish Date: April 19, 2021
Intervention Type: Drug
Study Phase: Phase 3
View 2 Less Clinical Trials

94 Total Publications

Osteoporosis and Fracture Risk in Ovarian Cancer: Beyond the Oncologic Burden.
Osteoporosis and Fracture Risk in Ovarian Cancer: Beyond the Oncologic Burden.
Journal: Diagnostics (Basel, Switzerland)
Published: October 17, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Arnaldi's expertise for a condition
ConditionClose
    View All 13 Advanced Conditions
    View All 20 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile